Samsung Bioepis Reports Record Annual Revenue on Strong Biosimilar Sales
Samsung Bioepis achieved record annual revenue in 2025, driven by strong biosimilar sales in the US and Europe, while expanding its pipeline and launching new products.
Samsung Biologics delivered record Q3 earnings, with revenue and profit soaring on full plant utilization, strong biosimilar sales, and favorable FX, beating market forecasts and signaling sustained order growth.
#YonhapInfomax #SamsungBiologics #Q3Earnings #BiosimilarSales #OperatingProfit #OrderGrowth #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=87675
Factory Utilization at Full Capacity, Biosimilar Sales Surge—Samsung Biologics Posts Surprise Q3 Earnings Beat (Comprehensive)
Samsung Biologics delivered record Q3 earnings, with revenue and profit soaring on full plant utilization, strong biosimilar sales, and favorable FX, beating market forecasts and signaling sustained order growth.
Samsung Biologics Posts Record Q3 Operating Profit of 728.8 Billion Won, Up 115.27%—Delivers Surprise Earnings (Update)
Samsung Biologics delivered record Q3 results, with operating profit soaring 115% to 728.8 billion won, far surpassing forecasts on robust biosimilar sales and full plant utilization.
Samsung Biologics is expected to maintain solid Q2 earnings as increased plant utilization and biosimilar sales offset the impact of a weaker dollar-won exchange rate, with analysts forecasting 17.1% revenue growth year-on-year.
#YonhapInfomax #SamsungBiologics #Q2Earnings #ExchangeRate #PlantUtilization #BiosimilarSales #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=71695
Samsung Biologics Expected to Defend Q2 Earnings Despite Weaker Dollar as Plant Utilization Rises
Samsung Biologics is expected to maintain solid Q2 earnings as increased plant utilization and biosimilar sales offset the impact of a weaker dollar-won exchange rate, with analysts forecasting 17.1% revenue growth year-on-year.
Celltrion's Q1 results expected to miss market estimates due to decreased sales of existing products and increased costs for US tariff preparation, despite significant year-on-year profit growth attributed to base effects.
#YonhapInfomax #Celltrion #Q1Performance #USTariffs #BiosimilarSales #OperatingProfit #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=61864
Celltrion's Q1 Performance Expected to Fall Short of Estimates Due to US Tariff Preparations
Celltrion's Q1 results expected to miss market estimates due to decreased sales of existing products and increased costs for US tariff preparation, despite significant year-on-year profit growth attributed to base effects.
Yonhap Infomax News